Ernexa Therapeutics (ERNA) Operating Leases (2018 - 2025)
Historic Operating Leases for Ernexa Therapeutics (ERNA) over the last 8 years, with Q3 2025 value amounting to $552000.0.
- Ernexa Therapeutics' Operating Leases fell 2489.8% to $552000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $552000.0, marking a year-over-year decrease of 2489.8%. This contributed to the annual value of $684000.0 for FY2024, which is 9804.96% down from last year.
- According to the latest figures from Q3 2025, Ernexa Therapeutics' Operating Leases is $552000.0, which was down 2489.8% from $593000.0 recorded in Q2 2025.
- Ernexa Therapeutics' Operating Leases' 5-year high stood at $40.3 million during Q2 2024, with a 5-year trough of $552000.0 in Q3 2025.
- Moreover, its 5-year median value for Operating Leases was $2.1 million (2021), whereas its average is $11.1 million.
- In the last 5 years, Ernexa Therapeutics' Operating Leases soared by 4811334.0% in 2021 and then tumbled by 9852.89% in 2025.
- Quarter analysis of 5 years shows Ernexa Therapeutics' Operating Leases stood at $2.4 million in 2021, then crashed by 63.21% to $887000.0 in 2022, then skyrocketed by 3853.78% to $35.1 million in 2023, then tumbled by 98.05% to $684000.0 in 2024, then dropped by 19.3% to $552000.0 in 2025.
- Its last three reported values are $552000.0 in Q3 2025, $593000.0 for Q2 2025, and $632000.0 during Q1 2025.